Inflammation News and Research

RSS

Ariel Pharmaceuticals in-licenses AP-1531 from BTG for acute migraine attacks

Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of products for acute central nervous system (CNS) diseases and trauma, announced today that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare company BTG International Ltd.

22 Sep 2011

Isolating 'bad' cells in rodent experiments may hold key to improving treatment for heart attacks

A UCSF study holds clues to why an emerging clinical trials option for heart attack patients has not been as successful as anticipated. Treatment of human hearts with bone marrow cells has led to limited to no success in improving their heart function even though a similar method has been much more effective in rodents.

21 Sep 2011

New FDA-approved antiviral drugs offer treatment hope for hepatitis C

The Methodist Hospital in Houston is excited to share significant news for patients who need treatment for hepatitis C genotype 1, a viral infection that causes liver inflammation that can lead to diminished liver function or symptoms for liver failure.

21 Sep 2011

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., today announced an agreement to expand Bristol-Myers Squibb's territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic alliance for the co-development and co-commercialization of ORENCIA in Japan.

21 Sep 2011

Depression may increase risk of stroke and death

An analysis of nearly 30 studies including more than 300,000 patients finds that depression is associated with a significantly increased risk of developing stroke and dying from stroke, according to an article in the September 21 issue of JAMA.

21 Sep 2011

Akeso Medical Imaging closes first financing round to develop imaging device for rheumatoid arthritis disease activity monitoring and control

Akeso Medical Imaging BV, a spin-off from Philips Research, announces today the closure of its first financing round led by Thuja Capital Healthcare Seed Fund with additional financing from the Brabant Spin-Off Fund and Point-One Innovation Fund.

20 Sep 2011

Water plays a decisive role in biologically active enzyme substrate compounds

In biologically active enzyme substrate compounds, as can be found in medicines, water plays a more decisive role than has been imagined up to now. The surrounding water acts like an "adhesive", in order to keep the substrate at the right place on an enzyme.

20 Sep 2011

Liposomes block HIV infection in early tests

Could engineered fatty particles help prevent AIDS? Liposomes block HIV infection in early tests; could be a cost-effective preventive for developing countries

20 Sep 2011

Individuals without ubiquitin ligase Nedd4L more likely to develop CF

Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator.

20 Sep 2011

ACR launches Simple Tasks campaign to raise awareness on rheumatic diseases

The American College of Rheumatology has launched its Simple Tasks campaign. The initiative aims to raise awareness of the severe impact of rheumatic diseases - such as rheumatoid arthritis, lupus and gout - on the U.S. population and to highlight the importance of rheumatologists in the diagnosis and treatment of these diseases.

20 Sep 2011

Calgary researchers discover new class of anti-inflammatory agents

By using a mouse model of inflammation researchers at the University of Calgary have discovered a new class of molecules that can inhibit the recruitment of some white blood cells to sites of inflammation in the body.

20 Sep 2011

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.

19 Sep 2011

USPTO issues notice of allowance to Cenestra Health's omega-3 fatty acid formulations

The U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance related to Cenestra Health's high-purity omega-3 fatty acid formulations and their methods of use.

19 Sep 2011

NTNU genetic research shows best recipe to limit risk of lifestyle-related diseases

What should we eat? Answers abound in the international media, all of which rely on their interpretation of recent medical literature to come up with recommendations for the healthiest diet. But what if you could answer this question at a molecular level - what if you could find out how our genes respond to the foods we eat, and what this does to the cellular processes that make us healthy - or not? That's precisely what biologists at the Norwegian University of Science and Technology have done.

19 Sep 2011

Scuba diving linked to improved PTSD symptoms in veterans with spinal cord injuries

A small group of veterans with spinal cord injuries who underwent a four-day scuba- diving certification saw significant improvement in muscle movement, increased sensitivity to light touch and pinprick on the legs, and large reductions in post-traumatic stress disorder (PTSD) symptoms, according to Johns Hopkins researchers.

19 Sep 2011

Landmark international study confirms common genetic contribution to mental illness

An international research consortium has confirmed that common genetic variants contribute to a person’s risk of schizophrenia and bipolar disorder. The largest study of its kind provides new molecular evidence that 11 regions have strong association with these diseases, including six regions not previously observed. The researchers also found that many of these DNA variations contribute to both diseases. The findings, reported by the Psychiatric Genome-Wide Association Study Consortium (PGC) and published online in two papers in the journal Nature Genetics, represent significant advances in the understanding the causes of these severe and often debilitating disorders.

18 Sep 2011

Emergency mosquito control operations in flood affected Pennsylvania counties

The Department of Environmental Protection announced today it will begin conducting emergency mosquito control operations in 18 counties affected by flooding.

17 Sep 2011

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Novartis announced today positive results of the first pivotal Phase III trial of ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease. The results, presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, showed all primary and secondary endpoints of the study were met.

17 Sep 2011

InNexus Biotechnology announces incentive stock options

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announces that it has, effective August 26, 2011, granted incentive stock options to purchase an aggregate of 1,068,683 common shares without par value in the capital of the Company to certain persons who are either a director, officer, employee or consultant of the Company.

17 Sep 2011

New insight into how nervous system regulates immunity

Scientists have identified a surprising new role for a new type of T cell in the immune system: some of them can be activated by nerves to make a neurotransmitter (acetylcholine) that blocks inflammation. The discovery of these T cells is novel and suggests that it may be possible to treat inflammation and autoimmune diseases by targeting the nerves and the T cells. The study was published this week in Science.

17 Sep 2011

Inflammation News and Research

Ariel Pharmaceuticals in-licenses AP-1531 from BTG for acute migraine attacks

Isolating 'bad' cells in rodent experiments may hold key to improving treatment for heart attacks

New FDA-approved antiviral drugs offer treatment hope for hepatitis C

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Depression may increase risk of stroke and death

Akeso Medical Imaging closes first financing round to develop imaging device for rheumatoid arthritis disease activity monitoring and control

Water plays a decisive role in biologically active enzyme substrate compounds

Liposomes block HIV infection in early tests

Individuals without ubiquitin ligase Nedd4L more likely to develop CF

ACR launches Simple Tasks campaign to raise awareness on rheumatic diseases

Calgary researchers discover new class of anti-inflammatory agents

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

USPTO issues notice of allowance to Cenestra Health's omega-3 fatty acid formulations

NTNU genetic research shows best recipe to limit risk of lifestyle-related diseases

Scuba diving linked to improved PTSD symptoms in veterans with spinal cord injuries

Landmark international study confirms common genetic contribution to mental illness

Emergency mosquito control operations in flood affected Pennsylvania counties

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

InNexus Biotechnology announces incentive stock options

New insight into how nervous system regulates immunity

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News